



PATENT
Docket No. 290.0009 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Michael S. Kinch et al.)	Group Art Unit:	1642
)		
Serial No.:	09/640,952)	Examiner:	Natalie A. Davis
Confirmation No.:	3252)		
)		
Filed:	August 17, 2000)		
)		
For:	EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)			

#9
SQJ
10/20/01

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed are copies of documents which Applicants bring to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of MPEP §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

The present application names joint inventors. To assist the Examiner in evaluating the application under 35 U.S.C. 102(f) and 102(g), and in accordance with their obligations under 37 C.F.R. 1.56, Applicants point out the inventor(s), the relative invention date of each claim, and the ownership at the time a later invention was made.

Supplemental Information Disclosure Statement

Page 2 of 3

Applicant(s): Michael S. Kinch et al.

Serial No.: 09/640,952

Confirmation No.: 3252

Filed: August 17, 2000

For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

Claims	Inventor(s)	Date invented (in relative terms)	Owner (at the time of the latest invention)
D7 hybridomas and antibodies, and methods of making Claims 14-17, 20, 82, 84, 89	Michael Kinch Katherine Kilpatrick	Earliest (first)	University of North Carolina, GlaxoSmithKline
isolated D7 hybridomas, antibodies Claims 83, 85	Michael Kinch Katherine Kilpatrick	Later (second)	Purdue Research Foundation, GlaxoSmithKline
diagnostic methods and compositions; antibodies that interact with EphA2 and hybridomas Claims 1-13, 18-19, 21-81, 86-88	Michael Kinch Nicole Zantek	Latest (third)	Purdue Research Foundation

Ownership is based upon the inventor's duty to assign at the time the invention was made, as presently understood by Applicants' Representative.

Since this Supplemental Information Disclosure Statement is submitted after receipt of an Office Action in the above-identified patent application, Applicants have included the fee of \$180 under 37 CFR §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

Supplemental Information Disclosure Statement

Page 3 of 3

Applicant(s): Michael S. Kinch et al.

Serial No.: 09/640,952

Confirmation No.: 3252


Filed: August 17, 2000

For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Gara L. Ladwig

"Express Mail" number: EL 888271719 US

Date of Deposit: October 5, 2001

5 October 2001
Date

Respectfully submitted for

Michael S. Kinch et al.

By

Muetting, Raasch & Gebhardt, P.A.


P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Facsimile (612)305-1228

Customer Number 26813

By: 

Victoria A. Sandberg

Reg. No. 41,287

Direct Dial (612)305-1226